Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms AMS-025, [18F]AMS-025 |
Target |
Action modulators |
Mechanism PSMA modulators(Prostate-specific membrane antigen modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Prostatic Cancer | Clinical | - | 27 May 2026 |





